Levilimab: meta-analysis of COVID-19 studies

All studies   Mortality   ICU   Serious outcomes   RCTs   RCT mortality   Peer-reviewed   All outcomes  
Meta-analysis1 study · 206 patientsc19early.org

Levilimab for COVID-19

Serious outcome risk
Levilimab
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)0%
Mortality (1)0%
ICU admission (1)70%
RCTs (1)0%
Late (1)0%
00.511.5+
← Levilimab
reduces riskIncreased
risk →
c19early.org
October 2026

Levilimab COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lomakin (DB RCT)0%1.00 · 0.26–3.89death4/1034/103CORONA
Late treatment0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Levilimab
reduces riskLevilimab
increases risk →
c19early.org
October 2026

Levilimab COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Lomakin (DB RCT)0%1.00 · 0.26–3.894/1034/103CORONA
Late treatment0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Levilimab
reduces riskLevilimab
increases risk →
c19early.org
October 2026

Levilimab COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Lomakin (DB RCT)70%0.30 · 0.09–1.063/10310/103CORONA
Late treatment70%0.30 · 0.09–1.063/10310/10370% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.061
All studies70%0.30 · 0.09–1.063/10310/10370% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.06100.511.52+
Rotate screen for more detailsIncrease width for more details
← Levilimab
reduces riskLevilimab
increases risk →
c19early.org
October 2026

Levilimab COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lomakin (DB RCT)0%1.00 · 0.26–3.89death4/1034/103CORONA
Late treatment0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Levilimab
reduces riskLevilimab
increases risk →
c19early.org
October 2026

Levilimab COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lomakin (DB RCT)0%1.00 · 0.26–3.89death4/1034/103CORONA
Late treatment0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Levilimab
reduces riskLevilimab
increases risk →
c19early.org
October 2026

Levilimab COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Lomakin (DB RCT)0%1.00 · 0.26–3.894/1034/103CORONA
Late treatment0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Levilimab
reduces riskLevilimab
increases risk →
c19early.org
October 2026

Levilimab COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Lomakin (DB RCT)0%1.00 · 0.26–3.89death4/1034/103CORONA
Late treatment0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.
All studies0%1.00 · 0.26–3.894/1034/1030% lower risk
Tau² = 0.00, I² = 0.0%, p = 1.00.511.52+
Rotate screen for more detailsIncrease width for more details
← Levilimab
reduces riskLevilimab
increases risk →